Krop Julie 4

What Happened

• Julie Krop, a director of Aquestive Therapeutics (AQST), exercised 25,000 stock options at $0.71 per share (cost $17,830) and the same day sold 25,000 shares in the open market at $5.02 per share for $125,393. The transactions were reported on a Form 4 covering activity dated 2026-06-23. This is a net sale of shares (often routine) executed under a pre-established plan.

Key Details

• Transaction date: June 23, 2026
• Exercise: 25,000 shares exercised at $0.71 each — total cost reported $17,830 (code M)
• Sale: 25,000 shares sold at $5.02 each — total proceeds $125,393 (code S)
• Additional line: a derivative (M) disposition of 25,000 shares at $0.00 is reported on the form (see footnotes)
• Footnotes: F1/F2 — transactions were effected pursuant to a Rule 10b5-1 trading plan; F3 — the option was granted June 22, 2022 and is fully vested
• Filing timeliness: Report filed 2026-06-24 for activity on 2026-06-23 (timely)
• Shares owned after transaction: Not specified in the provided filing excerpt

Context

• The Form 4 shows an exercise and a same-day sale, consistent with a planned sell under a 10b5-1 arrangement; the filing itself indicates the sales were made pursuant to a 10b5-1 trading plan. Derivative-code M lines indicate option exercise/conversion. The filing is factual and does not state the insider's motivation.